{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:18:49Z","timestamp":1787843929863,"version":"build-2784847793"},"reference-count":53,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting over 200 million people globally. Emerging IL\u20104R\u03b1\u2013targeted monoclonal antibodies have demonstrated strong efficacy and safety in clinical trials, warranting comparison with dupilumab, the current systemic standard. This meta\u2010analysis synthesises available evidence on their efficacy and safety. PubMed, Embase and Cochrane Library were systematically searched in April 2025 for randomised controlled trials (RCTs) comparing IL\u20104R\u03b1\u2013targeting monoclonal antibodies versus placebo in moderate\u2010to\u2010severe AD, with EASI\u201075 as the primary outcome. Non\u2010RCTs and trials using concomitant corticosteroids were excluded. Risk of bias was assessed using the Cochrane RoB\u20102 tool. Analyses were performed in R (v4.5.0), with heterogeneity evaluated by Cochran Q and\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    statistics. Nineteen RCTs comprising 4465 patients met inclusion criteria. At week 16, IL\u20104R\u03b1 inhibitors showed sustained efficacy across EASI\u201050\/75\/90, IGA 0\/1 and pruritus reduction. Dupilumab remained the most validated agent, with durable effects, low heterogeneity and favourable safety. Among novel biologics, stapokibart and rademikibart demonstrated the most promising results, achieving superior EASI\u201090 and \u2265\u20094\u2010point PP\u2010NRS responses: stapokibart (OR 4.94; 95% CI 3.20\u20137.61) and rademikibart (OR 4.61; 95% CI 1.68\u201312.65), though the latter showed higher odds of adverse events. Other agents (MG\u2010K10, GR1802, 611, AK120) provided encouraging but limited data. IL\u20104R\u03b1 inhibitors represent effective and safe therapies for moderate\u2010to\u2010severe AD. Dupilumab remains the reference standard, while stapokibart and rademikibart emerge as promising next\u2010generation options. Further large, long\u2010term, head\u2010to\u2010head RCTs are warranted to confirm their comparative performance.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PROSPERO Registration:<\/jats:bold>\n                    CRD420251129343.\n                  <\/jats:p>","DOI":"10.1111\/ajd.70138","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:26:32Z","timestamp":1778574392000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of\n                    <scp>IL<\/scp>\n                    \u2010\n                    <scp>4R\u03b1<\/scp>\n                    Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8714-2962","authenticated-orcid":false,"given":"Ana Carolina Putini","family":"Vieira","sequence":"first","affiliation":[{"name":"Division of Medicine University of Santo Amaro  S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7206-6601","authenticated-orcid":false,"given":"Ellen","family":"de Freitas Rezende","sequence":"additional","affiliation":[{"name":"Division of Medicine University of Santo Amaro  S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8727-0522","authenticated-orcid":false,"given":"Ana Carolina Ventura Santana","family":"de Jesus","sequence":"additional","affiliation":[{"name":"Division of Medicine Bahiana School of Medicine and Public Health  Salvador Bahia Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-9256","authenticated-orcid":false,"given":"Arianne Costa","family":"Baqui\u00e3o","sequence":"additional","affiliation":[{"name":"Division of Medicine University of Santo Amaro  S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02519-4"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.06.001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad339"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14276"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155664"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001352\u2010y"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10\u201071"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S389865"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100042"},{"key":"e_1_2_10_15_1","volume-title":"A Study to Evaluate the Efficacy and Safety of CBP\u2010201 in Moderate to Severe Atopic Dermatitis in China","author":"Connect Biopharm LLC","year":"2025"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.924"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13656"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/6903760"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001010\u20101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.775"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001368\u20104"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1447"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002747"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010025\u201002151\u20107"},{"key":"e_1_2_10_25_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)","author":"Higgins J. P. T.","year":"2024"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13016"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cesm.12033"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)00388\u20108"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15905"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20690"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201000965\u20105"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010020\u201000527\u2010x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000685\u20100"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1574"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110721"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0455"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2192"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010024\u201000668\u2010z"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16368"},{"key":"e_1_2_10_50_1","volume-title":"Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate\u2010to\u2010Severe Atopic Dermatitis","author":"Akesobio Australia Pty Ltd","year":"2025"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010024\u201002095\u20104"},{"key":"e_1_2_10_52_1","volume-title":"Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis","author":"Genrix (Shanghai) Biopharmaceutical Co. Ltd","year":"2024"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010020\u201000577\u20101"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072487"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:33:28Z","timestamp":1787841208000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ajd.70138"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70138","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2026-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}